- Conditions
- Liver Cirrhoses, Portal Hypertension Related to Cirrhosis, Severe Obesity, TIPS
- Interventions
- Transjugular Intrahepatic Portosystemic Shunt (TIPS), Sleeve Gastrectomy, Anti-Obesity Pharmacotherapy (Class Effect), Lifestyle Counseling - Diet & Physical-Activity Program
- Procedure · Drug · Behavioral
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2034
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 62
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
- Interventions
- Pegozafermin, Placebo
- Biological · Drug
- Lead sponsor
- 89bio, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 762 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 150
- States / cities
- Birmingham, Alabama • Homewood, Alabama • Chandler, Arizona + 123 more
- Conditions
- MASH
- Interventions
- RO7790121
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 11
- States / cities
- Tucson, Arizona • Marietta, Georgia • Bastrop, Louisiana + 8 more
- Conditions
- MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis), Fatty Liver Disease, Nonalcoholic
- Interventions
- Thermoacoustic Enhanced Ultrasound
- Device
- Lead sponsor
- Endra Lifesciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Liver Cirrhosis
- Interventions
- BI 3802876, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 26
- States / cities
- Chandler, Arizona • Coronado, California • La Mesa, California + 21 more
- Conditions
- MASH
- Interventions
- OPK-88006, Placebo
- Drug
- Lead sponsor
- OPKO Health, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Metabolic Associated-dysfunction Steatotic Liver Disease (MASLD), Metabolic Associated-dysfunction Steatohepatitis (MASH)
- Interventions
- Standard of care acceptance-based behavioral weight loss program, Occupational therapy dietary and lifestyle modifications
- Behavioral
- Lead sponsor
- Grand Valley State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Wyoming, Michigan
- Conditions
- Metabolic Dysfunction-associated Steatohepatitis
- Interventions
- Efimosfermin alfa, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 380 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 18
- States / cities
- Little Rock, Arkansas • Folsom, California • Miami, Florida + 13 more
- Conditions
- Obesity, Obesity (Body Mass Index >30 kg/m2)
- Interventions
- Endoscopic Sleeve Gastroplasty (ESG), Fundal Mucosal Ablation
- Device · Procedure
- Lead sponsor
- West Virginia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Alpha 1-Antitrypsin Deficiency
- Interventions
- BMN 349, Placebo
- Drug
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 4
- States / cities
- San Diego, California • St Louis, Missouri • Cincinnati, Ohio + 1 more
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- Interventions
- ALN-PNP, Tirzepatide, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 9
- States / cities
- Tucson, Arizona • Coronado, California • Pasadena, California + 6 more
- Conditions
- MASH - Metabolic Dysfunction-Associated Steatohepatitis
- Interventions
- Rezdiffra
- Drug
- Lead sponsor
- Madrigal Pharmaceuticals, Inc.
- Industry
- Eligibility
- Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- West Conshohocken, Pennsylvania
- Conditions
- Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Interventions
- Miricorilant (Cohort A), Placebo (Cohort A), Miricorilant (Cohort B), Placebo (Cohort B)
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 48
- States / cities
- Chandler, Arizona • Tucson, Arizona • Huntington Park, California + 41 more
- Conditions
- NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
- Interventions
- Efruxifermin, Placebo
- Drug
- Lead sponsor
- Akero Therapeutics, Inc
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 2,150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 169
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 141 more
- Conditions
- Obesity and Obesity-related Medical Conditions, Diabetes, Atherosclerotic Disease, Heart Failure, MASH, Sarcopenia, Osteoporosis, Hyperparathyroidism, Hypoparathyroidism, Ischemic Heart Disease, Cystic Fibrosis (CF), Chronic Kidney Disease(CKD), Osteopenia, Cachexia
- Interventions
- Endothelial cell collection
- Other
- Lead sponsor
- Bettina Mittendorfer
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2027 – 2030
- U.S. locations
- 1
- States / cities
- Columbia, Missouri
- Conditions
- Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Interventions
- VV-14303
- Genetic
- Lead sponsor
- Kriya Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 2
- States / cities
- Chandler, Arizona • Lady Lake, Florida
- Conditions
- NASH/MASH, NAFLD/MASLD
- Interventions
- Efruxifermin, Placebo
- Drug
- Lead sponsor
- Akero Therapeutics, Inc
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 139
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Flagstaff, Arizona + 117 more
- Conditions
- Metabolic Dysfunction-associated Steatohepatitis
- Interventions
- Efimosfermin alfa, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,740 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 13
- States / cities
- Little Rock, Arkansas • Folsom, California • Miami, Florida + 8 more
- Conditions
- NAFLD, NASH
- Interventions
- DD01, Placebo
- Drug
- Lead sponsor
- Neuraly, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 12
- States / cities
- Maitland, Florida • Monroe, Louisiana • West Monroe, Louisiana + 8 more
- Conditions
- MASH - Metabolic Dysfunction-Associated Steatohepatitis, Heart Failure With Preserved Ejection Fraction (HFPEF)
- Interventions
- Resmetirom, Placebo
- Drug
- Lead sponsor
- Madrigal Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 5
- States / cities
- Peoria, Arizona • Oxnard, California • Fort Myers, Florida + 2 more
- Conditions
- MASLD, MASH, Fibrosis, Liver, Chronic Liver Disease
- Interventions
- Endoscopic Ultrasound Shear Wave Elastography (EUS) and Attenuation Imaging, FibroScan, Liver biopsy
- Device
- Lead sponsor
- Olympus Corporation of the Americas
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Danville, Pennsylvania
- Conditions
- MASH - Metabolic Dysfunction-Associated Steatohepatitis, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), Fibrosis and Cirrhosis of Liver, MetALD
- Interventions
- Not listed
- Lead sponsor
- Active Genomes Expressed Diagnostics, Corp
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Liver Fibrosis, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Interventions
- Dietary Supplement/Behavioral: Navy Bean-Rich Diet, Habitual Diet (Control)
- Other
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis, Obesity
- Interventions
- Metabolic surgery, Incretin-Based Therapy
- Procedure · Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2029
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Indianapolis, Indiana • Rochester, Minnesota + 1 more